{"id":4008,"date":"2023-06-22T13:03:32","date_gmt":"2023-06-22T13:03:32","guid":{"rendered":"https:\/\/www.everpharma.com\/?p=4008"},"modified":"2024-03-13T12:46:34","modified_gmt":"2024-03-13T12:46:34","slug":"ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin","status":"publish","type":"post","link":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/","title":{"rendered":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin"},"content":{"rendered":"\n<div class=\"wp-block-columns is-style-default is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p class=\"wp-block-paragraph\"><strong>EVER Pharma freut sich, die EU-weite Zulassung von Trabectedin (0,25MG und 1MG) f\u00fcr die Behandlung von fortgeschrittenen Weichteilsarkomen und Eierstockkrebs<strong><sup>1<\/sup><\/strong> bekannt zu geben.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Weichteilsarkome und Eierstockkrebs sind seltene Krebsarten, von denen in der Europ\u00e4ischen Union insgesamt etwa 150 000 Patient*innen&nbsp;betroffen sind. Trabectedin wird f\u00fcr die Behandlung des fortgeschrittenen Weichteilsarkoms&nbsp;empfohlen<sup>2<\/sup>. Es ist auch eine wichtige Behandlungsoption f\u00fcr Patientinnen mit rezidivierendem Eierstockkrebs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8222;Seltene und fortgeschrittene Krebsarten sind im Hinblick auf die verf\u00fcgbaren Therapeutika oft unterbehandelt. EVER Pharma freut sich, Patient*innen, die mit diesen Krebsarten leben, dieses komplexe und technisch anspruchsvolle Produkt zur Verf\u00fcgung stellen zu k\u00f6nnen. Dies ist Teil unseres Engagements, den Zugang der Patient*innen zu wichtigen Medikamenten zu verbessern&#8220;, sagte Georges Kahwati, General Manager von EVER Pharma.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Die europ\u00e4ische Zulassung von EVER Pharmas Trabectedin ist eine weitere wichtige Erg\u00e4nzung des schnell wachsenden EVER-Portfolios an injizierbaren Specialty Injectables. Das Produkt wird global eingef\u00fchrt.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-1024x1024.png\" alt=\"\" class=\"wp-image-4004\" srcset=\"https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-1024x1024.png 1024w, https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-300x300.png 300w, https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-150x150.png 150w, https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-768x768.png 768w, https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots.png 1200w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:63px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-wpco-accordion accordion\" id=\"accordion-4008-1\">\n<div class=\"wp-block-wpco-accordion-body accordion-item\"><div class=\"accordion-header\" id=\"accordion-4008-1-item-1-heading\"><button class=\"accordion-button has-theme-gray-background-color has-theme-copy-color\" data-bs-toggle=\"collapse\" data-bs-target=\"#accordion-4008-1-item-1-body\">Quellen<\/button><\/div><div class=\"accordion-collapse collapse\" id=\"accordion-4008-1-item-1-body\" aria-labelledby=\"accordion-4008-1-item-1-heading\" data-bs-parent=\"#accordion-4008-1\"><div class=\"accordion-body has-theme-light-gray-background-color has-theme-copy-color\">\n<p class=\"wp-block-paragraph\"><sup>1<\/sup>Trabectedin EVER Pharma ist angezeigt (i) bei Erwachsenen zur Behandlung des fortgeschrittenen Weichteilsarkoms nach Versagen von Anthrazyklinen und Ifosfamid bzw. bei Patienten, bei denen sich die Anwendung dieser Mittel nicht eignet. Die Wirksamkeitsdaten basieren vorwiegend auf Patienten mit Liposarkom und Leiomyosarkom, (ii) in Kombination mit pegyliertem liposomalem Doxorubicin (PLD) wird angewendet bei Patientinnen zur Behandlung eines platinsensiblen Ovarialkarzinomrezidivs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><br><sup>2<\/sup>Europ\u00e4ische Gesellschaft f\u00fcr Medizinische Onkologie &#8211; Europ\u00e4isches Referenznetzwerk f\u00fcr seltene solide Krebserkrankungen bei Erwachsenen (ESMO-EURACAN) Klinische Praxisleitlinien<br><\/p>\n<\/div><\/div><\/div>\n<\/div>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EVER Pharma freut sich, die EU-weite Zulassung von Trabectedin (0,25MG und 1MG) f\u00fcr die Behandlung von fortgeschrittenen Weichteilsarkomen und Eierstockkrebs1 bekannt zu geben. Weichteilsarkome und Eierstockkrebs sind seltene Krebsarten, von denen in der Europ\u00e4ischen Union insgesamt etwa 150 000 Patient*innen&nbsp;betroffen sind. Trabectedin wird f\u00fcr die Behandlung des fortgeschrittenen Weichteilsarkoms&nbsp;empfohlen2. Es ist auch eine wichtige Behandlungsoption &hellip; <a href=\"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/\">Weiterlesen<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4008","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin - EVER Pharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin - EVER Pharma\" \/>\n<meta property=\"og:description\" content=\"EVER Pharma freut sich, die EU-weite Zulassung von Trabectedin (0,25MG und 1MG) f\u00fcr die Behandlung von fortgeschrittenen Weichteilsarkomen und Eierstockkrebs1 bekannt zu geben. Weichteilsarkome und Eierstockkrebs sind seltene Krebsarten, von denen in der Europ\u00e4ischen Union insgesamt etwa 150 000 Patient*innen&nbsp;betroffen sind. Trabectedin wird f\u00fcr die Behandlung des fortgeschrittenen Weichteilsarkoms&nbsp;empfohlen2. Es ist auch eine wichtige Behandlungsoption &hellip; Weiterlesen\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/\" \/>\n<meta property=\"og:site_name\" content=\"EVER Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-22T13:03:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-13T12:46:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-1024x1024.png\" \/>\n<meta name=\"author\" content=\"Magdalena\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Magdalena\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/\"},\"author\":{\"name\":\"Magdalena\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#\\\/schema\\\/person\\\/fddfefac0cbd5adf0a20c4e09a52cd65\"},\"headline\":\"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin\",\"datePublished\":\"2023-06-22T13:03:32+00:00\",\"dateModified\":\"2024-03-13T12:46:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Trabectedin_Combination-Pack-Shots-1024x1024.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/\",\"name\":\"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin - EVER Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Trabectedin_Combination-Pack-Shots-1024x1024.png\",\"datePublished\":\"2023-06-22T13:03:32+00:00\",\"dateModified\":\"2024-03-13T12:46:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Trabectedin_Combination-Pack-Shots-1024x1024.png\",\"contentUrl\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Trabectedin_Combination-Pack-Shots-1024x1024.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/\",\"name\":\"EVER Pharma\",\"description\":\"Dedicated to health.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":[\"Organization\",\"MedicalOrganization\"],\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#organization\",\"name\":\"EVER Pharma\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/ever-pharma-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/ever-pharma-logo.png\",\"width\":240,\"height\":67,\"caption\":\"EVER Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"legalName\":\"EVER Neuro Pharma GmbH\",\"foundingDate\":\"1934-01-01\",\"description\":\"EVER Pharma is a fully integrated specialty pharmaceuticals company specializing in the research, development, and production of sterile injectables and specialty generics for neurology, oncology, intensive care, and hormone therapeutics worldwide.\",\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"Oberburgau 3\",\"addressLocality\":\"Unterach am Attersee\",\"addressRegion\":\"Ober\u00f6sterreich\",\"postalCode\":\"4866\",\"addressCountry\":\"AT\"},\"contactPoint\":{\"@type\":\"ContactPoint\",\"contactType\":\"customer service\",\"telephone\":\"+43 7665 20555 0\",\"email\":\"office@everpharma.com\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ever-pharma\\\/\",\"https:\\\/\\\/www.wikidata.org\\\/wiki\\\/Q30268961\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#\\\/schema\\\/person\\\/fddfefac0cbd5adf0a20c4e09a52cd65\",\"name\":\"Magdalena\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g\",\"caption\":\"Magdalena\"},\"sameAs\":[\"https:\\\/\\\/everpharma.com\"],\"url\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/author\\\/mschmitzberger\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin - EVER Pharma","robots":{"index":"noindex","follow":"follow"},"og_locale":"de_DE","og_type":"article","og_title":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin - EVER Pharma","og_description":"EVER Pharma freut sich, die EU-weite Zulassung von Trabectedin (0,25MG und 1MG) f\u00fcr die Behandlung von fortgeschrittenen Weichteilsarkomen und Eierstockkrebs1 bekannt zu geben. Weichteilsarkome und Eierstockkrebs sind seltene Krebsarten, von denen in der Europ\u00e4ischen Union insgesamt etwa 150 000 Patient*innen&nbsp;betroffen sind. Trabectedin wird f\u00fcr die Behandlung des fortgeschrittenen Weichteilsarkoms&nbsp;empfohlen2. Es ist auch eine wichtige Behandlungsoption &hellip; Weiterlesen","og_url":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/","og_site_name":"EVER Pharma","article_published_time":"2023-06-22T13:03:32+00:00","article_modified_time":"2024-03-13T12:46:34+00:00","og_image":[{"url":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-1024x1024.png","type":"","width":"","height":""}],"author":"Magdalena","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Magdalena","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/#article","isPartOf":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/"},"author":{"name":"Magdalena","@id":"https:\/\/www.everpharma.com\/de\/#\/schema\/person\/fddfefac0cbd5adf0a20c4e09a52cd65"},"headline":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin","datePublished":"2023-06-22T13:03:32+00:00","dateModified":"2024-03-13T12:46:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/www.everpharma.com\/de\/#organization"},"image":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/#primaryimage"},"thumbnailUrl":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-1024x1024.png","articleSection":["News"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/","url":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/","name":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin - EVER Pharma","isPartOf":{"@id":"https:\/\/www.everpharma.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/#primaryimage"},"image":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/#primaryimage"},"thumbnailUrl":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-1024x1024.png","datePublished":"2023-06-22T13:03:32+00:00","dateModified":"2024-03-13T12:46:34+00:00","breadcrumb":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/#primaryimage","url":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-1024x1024.png","contentUrl":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-1024x1024.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.everpharma.com\/de\/"},{"@type":"ListItem","position":2,"name":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin"}]},{"@type":"WebSite","@id":"https:\/\/www.everpharma.com\/de\/#website","url":"https:\/\/www.everpharma.com\/de\/","name":"EVER Pharma","description":"Dedicated to health.","publisher":{"@id":"https:\/\/www.everpharma.com\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.everpharma.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":["Organization","MedicalOrganization"],"@id":"https:\/\/www.everpharma.com\/de\/#organization","name":"EVER Pharma","url":"https:\/\/www.everpharma.com\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.everpharma.com\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2022\/07\/ever-pharma-logo.png","contentUrl":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2022\/07\/ever-pharma-logo.png","width":240,"height":67,"caption":"EVER Pharma"},"image":{"@id":"https:\/\/www.everpharma.com\/de\/#\/schema\/logo\/image\/"},"legalName":"EVER Neuro Pharma GmbH","foundingDate":"1934-01-01","description":"EVER Pharma is a fully integrated specialty pharmaceuticals company specializing in the research, development, and production of sterile injectables and specialty generics for neurology, oncology, intensive care, and hormone therapeutics worldwide.","address":{"@type":"PostalAddress","streetAddress":"Oberburgau 3","addressLocality":"Unterach am Attersee","addressRegion":"Ober\u00f6sterreich","postalCode":"4866","addressCountry":"AT"},"contactPoint":{"@type":"ContactPoint","contactType":"customer service","telephone":"+43 7665 20555 0","email":"office@everpharma.com"},"sameAs":["https:\/\/www.linkedin.com\/company\/ever-pharma\/","https:\/\/www.wikidata.org\/wiki\/Q30268961"]},{"@type":"Person","@id":"https:\/\/www.everpharma.com\/de\/#\/schema\/person\/fddfefac0cbd5adf0a20c4e09a52cd65","name":"Magdalena","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g","caption":"Magdalena"},"sameAs":["https:\/\/everpharma.com"],"url":"https:\/\/www.everpharma.com\/de\/author\/mschmitzberger\/"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/posts\/4008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/comments?post=4008"}],"version-history":[{"count":7,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/posts\/4008\/revisions"}],"predecessor-version":[{"id":4183,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/posts\/4008\/revisions\/4183"}],"wp:attachment":[{"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/media?parent=4008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/categories?post=4008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/tags?post=4008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}